These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 15464673)

  • 1. Long-term cardiovascular risk with protease inhibitors and management of the dyslipidemia.
    Kannel WB; Giordano M
    Am J Cardiol; 2004 Oct; 94(7):901-6. PubMed ID: 15464673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of dyslipidemia associated with Highly Active Antiretroviral Therapy (HAART) on cardiovascular risk and life expectancy.
    Grover SA; Coupal L; Gilmore N; Mukherjee J
    Am J Cardiol; 2005 Mar; 95(5):586-91. PubMed ID: 15721096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid abnormalities.
    Dube M; Fenton M
    Clin Infect Dis; 2003 Apr; 36(Suppl 2):S79-83. PubMed ID: 12652375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ritonavir-boosted protease inhibitors, Part 2: cardiac implications of lipid alterations.
    Cohen CJ
    AIDS Read; 2005 Oct; 15(10):528-32, 537-8. PubMed ID: 16265768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risks of cardiovascular disease in patients receiving antiretroviral therapy for HIV infection: implications for treatment.
    Steinhart CR; Emons MF
    AIDS Read; 2004 Feb; 14(2):86-90, 93-5. PubMed ID: 14997864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dyslipidemia in the era of HIV protease inhibitors.
    Stein JH
    Prog Cardiovasc Dis; 2003; 45(4):293-304. PubMed ID: 12638093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of dyslipidemia associated with protease inhibitors.
    Kapoor JR
    Am J Cardiol; 2009 Jan; 103(2):292-3. PubMed ID: 19121456
    [No Abstract]   [Full Text] [Related]  

  • 8. [HIV infection, antiretroviral therapy, and endothelium].
    Hürlimann D; Weber R; Enseleit F; Lüscher TF
    Herz; 2005 Sep; 30(6):472-80. PubMed ID: 16170677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The metabolic syndrome, an epidemic among HIV-infected patients on HAART.
    Jevtović DJ; Dragović G; Salemović D; Ranin J; Djurković-Djaković O
    Biomed Pharmacother; 2009 Jun; 63(5):337-42. PubMed ID: 18996676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Highly active antiretroviral therapy-associated metabolic syndrome: pathogenesis and cardiovascular risk.
    Barbaro G
    Am J Ther; 2006; 13(3):248-60. PubMed ID: 16772767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vascular injury, hypertension and coronary artery disease in human immunodeficiency virus infection.
    Barbaro G
    Clin Ter; 2008; 159(1):51-5. PubMed ID: 18399263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Lipodystrophy--an adverse effect of protease inhibitors used against HIV infection? Concern about negative delayed effects of this break-through].
    Morfeldt L; Jonsson B; Regnström J
    Lakartidningen; 1998 Oct; 95(42):4616-7. PubMed ID: 9814016
    [No Abstract]   [Full Text] [Related]  

  • 13. Cardiovascular events associated with the use of four nonselective NSAIDs (etodolac, nabumetone, ibuprofen, or naproxen) versus a cyclooxygenase-2 inhibitor (celecoxib): a population-based analysis in Taiwanese adults.
    Huang WF; Hsiao FY; Wen YW; Tsai YW
    Clin Ther; 2006 Nov; 28(11):1827-36. PubMed ID: 17213003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dyslipidaemia and cardiovascular risk in HIV infection.
    Kulasekaram R; Peters BS; Wierzbicki AS
    Curr Med Res Opin; 2005 Nov; 21(11):1717-25. PubMed ID: 16307691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular manifestations in human immunodeficiency virus-infected patients.
    Khunnawat C; Mukerji S; Havlichek D; Touma R; Abela GS
    Am J Cardiol; 2008 Sep; 102(5):635-42. PubMed ID: 18721528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of metabolic drugs and fish oil in HIV-positive patients with metabolic complications and associations with dyslipidaemia and treatment targets.
    Normén L; Yip B; Montaner J; Harris M; Frohlich J; Bondy G; Hogg RS
    HIV Med; 2007 Sep; 8(6):346-56. PubMed ID: 17661842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular risk score change in HIV-1-infected patients switched to an atazanavir-based combination antiretroviral regimen.
    Colafigli M; Di Giambenedetto S; Bracciale L; Tamburrini E; Cauda R; De Luca A
    HIV Med; 2008 Mar; 9(3):172-9. PubMed ID: 18217998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endoplasmic reticulum stress links dyslipidemia to inhibition of proteasome activity and glucose transport by HIV protease inhibitors.
    Parker RA; Flint OP; Mulvey R; Elosua C; Wang F; Fenderson W; Wang S; Yang WP; Noor MA
    Mol Pharmacol; 2005 Jun; 67(6):1909-19. PubMed ID: 15755908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The basis and management of metabolic abnormalities associated with cardiovascular risk in human immunodeficiency virus infection and its treatment.
    Crook M
    Ann Clin Biochem; 2007 May; 44(Pt 3):219-31. PubMed ID: 17456292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of treatment with protease inhibitors on aortic stiffness in adult patients with human immunodeficiency virus infection.
    Schillaci G; De Socio GV; Pirro M; Savarese G; Mannarino MR; Baldelli F; Stagni G; Mannarino E
    Arterioscler Thromb Vasc Biol; 2005 Nov; 25(11):2381-5. PubMed ID: 16123321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.